Answers are grounded in this paper and cite their sources.
Randomized trial assesses efficacy and safety of upadacitinib in atopic dermatitis patients, indicating effectiveness in real-world settings.
Purpose: Upadacitinib is an oral selective Janus kinase (JAK) 1 inhibitor that has demonstrated high efficacy in clinical trials for patients with atopic dermatitis (AD).However, clinical trial settings may not always reflect real-world practice.This study aimed to assess the real-world efficacy and safety of upadacitinib in AD patients.Methods: One hundred fifteen AD patients treated with upadacitinib were retrospectively analyzed using medical records.Patients who received treatment for at least 16 weeks were included.In the moderate-to-severe AD group, efficacy was assessed by the proportion of patients achieving Eczema Area and Severity Index (EASI) 50, EASI 75, and EASI 90 at weeks 2 and 16 compared to baseline, whereas efficacy in the mild AD group was evaluated based on the reduction in patient-reported outcomes. Results:The mean EASI score significantly decreased after 16 weeks of upadacitinib treatment.At week 2, 67%, 35%, and 6% of moderate-to-severe AD patients achieved EASI 50, EASI 75 and EASI 90, respectively.At week 16, 88%, 71%, and 31% of moderateto-severe AD patients achieved EASI 50, EASI 75 and EASI 90, respectively.Patient-reported outcome measures improved rapidly within 2 weeks and were sustained through week 16.The most common adverse event was acne, occurring in 35 patients (41.2%) with mild severity.No serious adverse events occurred.Conclusions: Upadacitinib is effective and safe for AD patients in a real-world clinical setting.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: